First-Line Antihypertensive Regimen
For most adults with newly diagnosed hypertension, initiate treatment with a thiazide or thiazide-like diuretic (preferably long-acting agents like chlorthalidone or indapamide), a long-acting dihydropyridine calcium channel blocker (CCB), an ACE inhibitor (ACEi), or an angiotensin receptor blocker (ARB)—these four drug classes are equally recommended as first-line monotherapy for uncomplicated hypertension. 1, 2, 3, 4
Initial Treatment Strategy
Monotherapy vs. Combination Therapy
The choice between starting with one drug versus two depends on how elevated the blood pressure is:
Stage 1 hypertension (BP 130-139/80-89 mm Hg or up to 20/10 mm Hg above target): Start with single-agent therapy 2, 3
Stage 2 hypertension (BP ≥140/90 mm Hg or >20/10 mm Hg above target): Consider initial combination therapy with two first-line agents, either as separate pills or preferably as a single-pill combination 1, 2, 3, 4
The 2024 ESC guidelines and 2025 AHA/ACC guidelines now favor upfront combination therapy for confirmed hypertension to achieve faster BP control and potentially improve adherence 3, 4. However, exercise caution in elderly or frail patients where excessive BP drops could be poorly tolerated 1.
Selecting the Specific First-Line Agent
For General Uncomplicated Hypertension
All four major classes are appropriate, but consider these nuances:
Thiazide/thiazide-like diuretics (Grade A evidence):
- Chlorthalidone specifically showed superiority over amlodipine and lisinopril in preventing heart failure in head-to-head trials 2
- Long-acting agents (chlorthalidone, indapamide) are preferred over shorter-acting hydrochlorothiazide 1
- Critical caveat: Monitor and avoid hypokalemia 1, 5
Long-acting dihydropyridine CCBs (Grade A-B evidence):
- Equally effective as thiazides for most cardiovascular outcomes except heart failure (where thiazides are superior) 2
- Good alternative when thiazides are not tolerated 2
ACE inhibitors (Grade B evidence):
- Effective in non-Black patients 1, 2
- Do NOT use as first-line in Black patients—they are notably less effective than CCBs and thiazides for stroke and heart failure prevention in this population (Grade A recommendation against) 1, 2
ARBs (Grade B evidence):
- Similar efficacy to ACE inhibitors
- Better tolerated than ACE inhibitors (less cough, less angioedema) 2
What NOT to Use First-Line
β-blockers:
- NOT recommended as first-line for uncomplicated hypertension in patients ≥60 years old (Grade A) 1, 2
- May be used in younger patients (<60 years) but are inferior to thiazides and CCBs for stroke prevention 2
- Reserve for patients with specific compelling indications (post-MI, heart failure, angina)
α-blockers:
- NOT recommended as first-line agents (Grade A)—less effective for CVD prevention than other classes 1, 2
Non-dihydropyridine CCBs:
- Significantly inferior to other first-line classes 6
Preferred Combination Regimens
When combination therapy is needed (most patients require ≥2 drugs):
Strongly recommended combinations:
- ACE inhibitor + CCB (Grade A) 1
- ARB + CCB (Grade B) 1
- ARB + thiazide diuretic (Grade B) 1
- Thiazide diuretic + dihydropyridine CCB (Grade B) 1
NEVER combine:
- ACE inhibitor + ARB (Grade A recommendation against) 1, 7
- ACE inhibitor or ARB + direct renin inhibitor 7
Use caution:
- Non-dihydropyridine CCB + β-blocker (risk of excessive bradycardia) 1
Special Population Considerations
Black patients:
Diabetes with albuminuria (ACR ≥30 mg/g):
Isolated systolic hypertension:
Very elderly (≥80 years):
- Same agents apply, but target SBP <150 mm Hg may be appropriate 9
Critical Implementation Points
Dose titration: If target BP not achieved with standard-dose monotherapy, add a second agent from first-line choices rather than maximizing the first drug 1
Single-pill combinations: Strongly preferred over separate pills when using combination therapy to improve adherence 4
Monitoring: Check serum creatinine, eGFR, and potassium at least annually when using ACE inhibitors, ARBs, or diuretics 7
Resistant hypertension: If uncontrolled on three first-line agents (including a diuretic), add spironolactone as fourth-line 4
The most recent high-quality evidence from the 2025 AHA/ACC guidelines 3 and 2024 ESC guidelines 4 confirms that thiazide-type diuretics, long-acting dihydropyridine CCBs, ACE inhibitors, and ARBs remain the cornerstone of first-line therapy, with real-world data from 2025 supporting thiazides' slight superiority over ACE inhibitors for composite cardiovascular outcomes 10.